

TITLE PAGE

Title : **Antibody persistency and dynamic trend after SARS-CoV-2 infection over 8 months**

Key words : “sars-cov-2” “covid19” “coronavirus” “antibody trend”

Authors:

1. Puya Dehgani-Mobaraki, M.D , M.S(ORL) [Corresponding author]

Affiliation: President of Associazione Naso Sano, Umbria region, Italy.

Email: dehganipuya@gmail.com

ORCID Id: 0000-0001-8339-1868

2. Asiya Kamber Zaidi, M.D, M.S (ORL), F.W.A.M.S

Affiliation: Senior Registrar, M.G.M Medical College and M.Y Hospital , Indore, M.P, India

Member, Associazione Naso Sano, Umbria region, Italy.

Email: asiyazaidia@gmail.com

ORCID Id: 0000-0001-6510-6365

3. Annamaria Porreca

Affiliation: Ph.D student at Department of Economics, University "G.d'Annunzio", chieti-Pescara, Italy

ORCID Id: 0000-0003-3278-1561

Email : porreca.annamaria@gmail.com

4. Alessandro Floridi , M.Pharm

Affiliation: Laboratory of Nuclear Lipid BioPathology, Centro Ricerche Analisi Biochimico Specialistiche, Perugia, Italy

Email: direzione@crabion.it

5. Emanuela Floridi,

Affiliation: Laboratory of Nuclear Lipid BioPathology, Centro Ricerche Analisi Biochimico Specialistiche, Perugia, Italy.

Email: emanuela@crabion.it

Antibody persistency and dynamic trend after SARS-CoV-2 infection over 8 months

Abstract:

An improved understanding of the immunity offered by the antibodies developed against SARS-CoV-2 is critical for the development of diagnostic tests and vaccines. Our study aimed at longitudinal analysis of antibody persistence and its dynamic trend over a period of eight months in a group of COVID-19 recovered patients who tested positive by real-time quantitative PCR for SARS-CoV-2 in the period between the 18th and 30th of March, 2020. The subjects were divided into two groups based on disease severity: mild and moderately-severe. The MAGLUMI® 2019-nCoV IgM/IgG chemiluminescent analytical system (CLIA) assay was used to analyse the antibody titres. Robust IgG antibody persistency was demonstrated in 76.7 % of the subjects (23 out of 30) at eight months post infection.

The results of this study highlight an important point in terms of the association between humoral immune response and disease severity. Patients who might have experienced a relatively moderate-severe infection may develop a robust immunity that could persist for a longer duration.

The immunity offered by the antibodies developed in patients recovered from COVID-19 is a matter of ongoing debate and encompasses genuine concern for the future. Recent studies and the media have focused their attention on the role of vaccines offering immunity and persistence of humoral response in recovered patients, ranging from four months [1] to more than six months [2] post infection.

A monocentric pilot longitudinal observational study was carried on 114 subjects based in the Umbria region in Italy, who had tested positive by real-time quantitative PCR for SARS-CoV-2 in the period between the 18th and the 30th of March, 2020. The demographic characteristics, blood groups, associated co-morbidities, clinical features, treatment undertaken and dates pertaining to symptom onset and swab collections were recorded. Sequential serum samples were collected over a period of eight months for 30 out of 114 subjects who attended all follow-up visits. The aim of this study was to investigate for presence, persistence and dynamic trend of IgM and IgG antibodies against SARS-CoV-2 over a period of time. The subjects participating in the study were divided into two groups based on disease severity: mild and moderately-severe. [3] All subjects were enrolled in the clinical registry and a written informed consent was obtained for voluntary participation in the study.

The MAGLUMI® 2019-nCoV IgM/IgG chemiluminescent analytical system (CLIA) assay was used to analyse the antibody titres. Results were reported as measured chemiluminescence values divided by the cut off (absorbance/cutoff, S/CO): $S/CO > 1$ was defined as positive and $S/CO \leq 1$ as negative. [4] We treated time as a factor and defined five different time points: first blood sample was collected in the month of May (T0) and then, one month after T0 (T1), three months after T0 (T2), five months after T0 (T3), six months after T0 (T4).

The Descriptive statistics for the main characteristics of the study group was expressed as Median, [1st-3rd] quartile for continuous variables and as absolute frequency (column percentage) for the categorical variables [Table 1]. The Chi squared test was used to measure the association between disease severity and the categorical variables, and the Mann U Whitney test was used to assess the differences between the disease severity for the continuous variables. Also, in order to analyse if there were significant differences between disease severity at each time point, the Mann U Whitney test was used. The Friedman test was applied to understand if there were statistically significant differences over time between the two severity groups for IgM and IgG. The normal distribution of the data was tested by Shapiro Wilks.

The positivity cut-off for CLIA was set at 1.01 and the median titre trend for IgM and IgG, for both mild and moderately-severe groups, were plotted. [FIGURE 1]

Robust IgG antibody persistency was demonstrated in 76.7 % of the subjects (23 out of 30) at eight months post infection. [FIGURE 2].

For the mild group, the IgM titre trend stayed below the set cut off for CLIA positivity throughout the time course, and changed in a statistically significant way. It was observed that the IgM titre trend peaked at T2 and then decreased with time, while the IgG titre trend peaked at T2 only to return to an almost linear trend at T3 and remained well above the cut-off throughout the time. This titre trend for IgG was not statistically significant for this group. Similar findings were observed in previous studies. [5,6]

For the moderately-severe group, the titre trend for both IgM and IgG changed in a statistically significant way throughout the time course with IgM below and IgG above the set cut off for CLIA positivity. (TABLE 2)

The results of this study highlight an important point in terms of association between humoral immune response and disease severity. Patients who might have experienced a relatively moderate-severe infection may develop a robust immunity that could persist for a longer duration.

REFERENCES:

1. Gudbjartsson DF et al. Humoral Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med*. 2020 Oct 29;383(18):1724-1734. doi: 10.1056/NEJMoa2026116. Epub 2020 Sep 1. PMID: 32871063; PMCID: PMC7494247.
2. <https://www.nytimes.com/2020/11/17/health/coronavirus-immunity.html>
3. [https://www.who.int/publications/i/item/global-surveillance-for-human-infection-with-novel-coronavirus-\(2019-ncov\)](https://www.who.int/publications/i/item/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)) **WHO REFERENCE NUMBER:** WHO/2019-nCoV/SurveillanceGuidance/2020.6
4. Puya Dehgani-Mobaraki, Asiya Kamber Zaidi, Alessandro Floridi, Alessandro Lepri, Emanuela Floridi, Alessia Gherardi, Enrico Bernini-Carri, Eleonora Durzo, Massoud Dehgani-Mobaraki. A comprehensive analysis of recovered COVID-19 patients and dynamic trend in antibodies over 3 months using ELISA and CLIA methods. medRxiv 2020.08.31.20184838; doi: <https://doi.org/10.1101/2020.08.31.20184838>
5. <https://www.nejm.org/doi/full/10.1056/NEJMc2027051>
6. https://www.nejm.org/doi/full/10.1056/NEJMc2025179?query=recirc_curatedRelated_article

Table 1. Descriptive statistics for the main characteristics of the study group was expressed as Median, [1st-3rd] quartile for continuous variables (A) and as absolute frequency (column percentage) for the categorical variables (B).

| (A) | | | |
|--------------------|----------------------|---------------------------------|----------------|
| Variable | Mild N=17 | Moderate-Severe N=13 | p-value |
| Age (years) | 39.0 [30.0;59.0] | 55.0 [38.0;57.0] | 0.645 |
| SEX: | | | 0.708 |
| F | 10 (58.8%) | 9 (69.2%) | |
| M | 7 (41.2%) | 4 (30.8%) | |
| Blood Group: | | | 0.360 |
| Other | 15 (88.2%) | 9 (69.2%) | |
| Zero | 2 (11.8%) | 4 (30.8%) | |
| Healthcare worker: | | | 0.599 |
| NO | 9 (52.9%) | 9 (69.2%) | |
| YES | 8 (47.1%) | 4 (30.8%) | |

| (B) | | | |
|------------------------------|----------------------|---------------------------------|----------------|
| Variable | Mild N=17 | Moderate-Severe N=13 | p-value |
| Asthma / seasonal allergies: | | | 0.355 |
| No | 13 (76.5%) | 12 (92.3%) | |
| YES | 4 (23.5%) | 1 (7.69%) | |
| Rhinorrhea: | | | 0.705 |
| No | 12 (70.6%) | 8 (61.5%) | |
| YES | 5 (29.4%) | 5 (38.5%) | |
| Dry cough: | | | 0.838 |
| No | 6 (35.3%) | 5 (38.5%) | |
| YES | 11 (64.7%) | 8 (61.5%) | |
| Sore throat: | | | 0.698 |
| No | 13 (76.5%) | 9 (69.2%) | |
| YES | 4 (23.5%) | 4 (30.8%) | |
| Shortness of breath: | | | <0.001 |
| No | 15 (88.2%) | 2 (15.4%) | |
| YES | 2 (11.8%) | 11 (84.6%) | |
| Fatigue: | | | 0.020 |
| No | 11 (64.7%) | 2 (15.4%) | |
| YES | 6 (35.3%) | 11 (84.6%) | |
| Headache: | | | 0.676 |

| Variable | Mild <i>N=17</i> | Moderate-Severe <i>N=13</i> | p-value |
|-----------------|-----------------------------|--|----------------|
| No | 9 (52.9%) | 5 (38.5%) | |
| YES | 8 (47.1%) | 8 (61.5%) | |
| Skin eruption: | | | 0.290 |
| No | 16 (94.1%) | 10 (76.9%) | |
| YES | 1 (5.88%) | 3 (23.1%) | |
| Muscle ache: | | | 0.691 |
| No | 6 (35.3%) | 3 (23.1%) | |
| YES | 11 (64.7%) | 10 (76.9%) | |
| Diarrhea: | | | 0.132 |
| No | 13 (76.5%) | 6 (46.2%) | |
| YES | 4 (23.5%) | 7 (53.8%) | |
| Conjunctivitis: | | | 0.427 |
| No | 12 (70.6%) | 11 (84.6%) | |
| YES | 5 (29.4%) | 2 (15.4%) | |
| Loss of Smell: | | | 0.698 |
| No | 4 (23.5%) | 4 (30.8%) | |
| YES | 13 (76.5%) | 9 (69.2%) | |
| Loss of taste: | | | 0.978 |
| No | 5 (29.4%) | 3 (23.1%) | |
| YES | 12 (70.6%) | 10 (76.9%) | |
| Chest pain: | | | 0.190 |
| No | 15 (88.2%) | 8 (61.5%) | |
| YES | 2 (11.8%) | 5 (38.5%) | |

Figure 1. Median trends for IgM and IgG for the two disease severity groups: mild and moderately severe. The dashed horizontal line shows the threshold (CLIA positivity Cut-off) for a sample being considered positive for antibodies.




Figure 2. Bar plot showing IgM and IgG positivity for all subjects of the study group (N=30) (CLIA cut-off >1.00)





Table 2. Friedman test for repeated measurements only for variables with a p-value <0.05 reporting the time pairs for which the test is statistically significant. PWC= pairwise comparisons.

| Mild | | | | | | | |
|-----------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------|-------|
| Variable | T0 | T1 | T2 | T3 | T4 | p-value | PWC |
| IgM | 0.50 [0.46;0.52] | 0.61 [0.52;0.64] | 0.36 [0.18;0.53] | 0.23 [0.17;0.33] | 0.21 [0.18;0.35] | <0.001 | T0≠T2 |
| | | | | | | | T0≠T3 |
| | | | | | | | T0≠T4 |
| | | | | | | | T1≠T2 |
| | | | | | | | T1≠T3 |
| T1≠T4 | | | | | | | |
| IgG | 1.84 [0.68;3.54] | 1.81 [0.56;2.90] | 1.70 [0.88;5.02] | 3.05 [0.50;3.80] | 3.13 [1.05;3.66] | 0.205 | |
| Moderate-Severe | | | | | | | |
| Variable | T0 | T1 | T2 | T3 | T4 | p-value | PWC |
| IgM | 0.64 [0.64;1.07] | 0.70 [0.66;1.44] | 0.66 [0.24;0.84] | 0.59 [0.31;0.82] | 0.54 [0.25;0.81] | <0.001 | T0≠T2 |
| | | | | | | | T0≠T3 |
| | | | | | | | T0≠T4 |
| | | | | | | | T1≠T3 |
| | | | | | | | T1≠T4 |
| T3≠T4 | | | | | | | |
| IgG | 2.37 [1.14;20.7] | 1.48 [0.83;20.6] | 4.10 [2.38;16.1] | 2.25 [1.04;10.2] | 1.89 [0.83;8.53] | 0.013 | T0≠T4 |
| | | | | | | | T2≠T3 |
| | | | | | | | T2≠T4 |
| | | | | | | | T3≠T4 |







Table 1. Descriptive statistics for the main characteristics of the study group was expressed as Median, [1st-3rd] quartile for continuous variables (A) and as absolute frequency (column percentage) for the categorical variables (B).

(A)

| Variable | Mild N=17 | Moderate-Severe N=13 | p-value |
|--------------------|------------------|-------------------------|---------|
| Age (years) | 39.0 [30.0;59.0] | 55.0 [38.0;57.0] | 0.645 |
| SEX: | | | 0.708 |
| F | 10 (58.8%) | 9 (69.2%) | |
| M | 7 (41.2%) | 4 (30.8%) | |
| Blood Group: | | | 0.360 |
| Other | 15 (88.2%) | 9 (69.2%) | |
| Zero | 2 (11.8%) | 4 (30.8%) | |
| Healthcare worker: | | | 0.599 |
| NO | 9 (52.9%) | 9 (69.2%) | |
| YES | 8 (47.1%) | 4 (30.8%) | |

(B)

| Variable | Mild N=17 | Moderate-Severe N=13 | p-value |
|------------------------------|--------------|-------------------------|---------|
| Asthma / seasonal allergies: | | | 0.355 |
| No | 13 (76.5%) | 12 (92.3%) | |
| YES | 4 (23.5%) | 1 (7.69%) | |
| Rhinorrhea: | | | 0.705 |
| No | 12 (70.6%) | 8 (61.5%) | |
| YES | 5 (29.4%) | 5 (38.5%) | |
| Dry cough: | | | 0.838 |
| No | 6 (35.3%) | 5 (38.5%) | |
| YES | 11 (64.7%) | 8 (61.5%) | |
| Sore throat: | | | 0.698 |
| No | 13 (76.5%) | 9 (69.2%) | |
| YES | 4 (23.5%) | 4 (30.8%) | |
| Shortness of breath: | | | <0.001 |
| No | 15 (88.2%) | 2 (15.4%) | |
| YES | 2 (11.8%) | 11 (84.6%) | |
| Fatigue: | | | 0.020 |
| No | 11 (64.7%) | 2 (15.4%) | |
| YES | 6 (35.3%) | 11 (84.6%) | |
| Headache: | | | 0.676 |

| Variable | Mild <i>N=17</i> | Moderate-Severe <i>N=13</i> | p-value |
|-----------------|-----------------------------|--|----------------|
| No | 9 (52.9%) | 5 (38.5%) | |
| YES | 8 (47.1%) | 8 (61.5%) | |
| Skin eruption: | | | 0.290 |
| No | 16 (94.1%) | 10 (76.9%) | |
| YES | 1 (5.88%) | 3 (23.1%) | |
| Muscle ache: | | | 0.691 |
| No | 6 (35.3%) | 3 (23.1%) | |
| YES | 11 (64.7%) | 10 (76.9%) | |
| Diarrhea: | | | 0.132 |
| No | 13 (76.5%) | 6 (46.2%) | |
| YES | 4 (23.5%) | 7 (53.8%) | |
| Conjunctivitis: | | | 0.427 |
| No | 12 (70.6%) | 11 (84.6%) | |
| YES | 5 (29.4%) | 2 (15.4%) | |
| Loss of Smell: | | | 0.698 |
| No | 4 (23.5%) | 4 (30.8%) | |
| YES | 13 (76.5%) | 9 (69.2%) | |
| Loss of taste: | | | 0.978 |
| No | 5 (29.4%) | 3 (23.1%) | |
| YES | 12 (70.6%) | 10 (76.9%) | |
| Chest pain: | | | 0.190 |
| No | 15 (88.2%) | 8 (61.5%) | |
| YES | 2 (11.8%) | 5 (38.5%) | |

Table 2. Friedman test for repeated measurements only for variables with a p-value <0.05 reporting the time pairs for which the test is statistically significant. PWC= pairwise comparisons.

| Mild | | | | | | | |
|-----------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------|-------|
| Variable | T0 | T1 | T2 | T3 | T4 | p-value | PWC |
| IgM | 0.50 [0.46;0.52] | 0.61 [0.52;0.64] | 0.36 [0.18;0.53] | 0.23 [0.17;0.33] | 0.21 [0.18;0.35] | <0.001 | T0≠T2 |
| | | | | | | | T0≠T3 |
| | | | | | | | T0≠T4 |
| | | | | | | | T1≠T2 |
| | | | | | | | T1≠T3 |
| | | | | | | | T1≠T4 |
| IgG | 1.84 [0.68;3.54] | 1.81 [0.56;2.90] | 1.70 [0.88;5.02] | 3.05 [0.50;3.80] | 3.13 [1.05;3.66] | 0.205 | |
| | | | | | | | |
| Moderate-Severe | | | | | | | |
| Variable | T0 | T1 | T2 | T3 | T4 | p-value | PWC |
| IgM | 0.64 [0.64;1.07] | 0.70 [0.66;1.44] | 0.66 [0.24;0.84] | 0.59 [0.31;0.82] | 0.54 [0.25;0.81] | <0.001 | T0≠T2 |
| | | | | | | | T0≠T3 |
| | | | | | | | T0≠T4 |
| | | | | | | | T1≠T3 |
| | | | | | | | T1≠T4 |
| | | | | | | | T3≠T4 |
| IgG | 2.37 [1.14;20.7] | 1.48 [0.83;20.6] | 4.10 [2.38;16.1] | 2.25 [1.04;10.2] | 1.89 [0.83;8.53] | 0.013 | T0≠T4 |
| | | | | | | | T2≠T3 |
| | | | | | | | T2≠T4 |
| | | | | | | | T3≠T4 |